In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable … More
Main Navigation Menu
➤ Asbestos Information Overview
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Mesothelioma, Asbestos Cancers, and Asbestos Diseases
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Some Information Concerning Our Law Firm
➤ A Brief Message from Attorney Tom Lamb
➤ Recent News & Reports: Asbestos / Mesothelioma
➤ Questions Clients Have Asked Us (FAQs)
➤ Sitemap for Asbestos-Mesothelioma.com
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent News & Reports
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
Background: The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical studies in solid tumours. We assessed the clinical activity of this combination therapy [ of pembrolizumab plus … More
Exhaled Breath May Predict Treatment Outcomes in Patients With Mesothelioma
The identification of volatile organic compounds (VOCs) in exhaled breath is a promising opportunity for noninvasive detection and prediction of treatment outcomes in patients with mesothelioma, according to data from a pilot study presented at the International Association for the Study of Lung … More
Study Questions Use of Aggressive Surgery in Early Mesothelioma
Extended pleurectomy/decortication combined with platinum and pemetrexed chemotherapy was associated with worse outcomes in patients with resectable mesothelioma compared with chemotherapy alone, according to a randomized trial. "As a surgeon, you have no idea how much it pains me to conclude … More
Feladilimab by GSK for Malignant Pleural Mesothelioma: Likelihood of Approval
[Feladilimab] is under development [by the pharmaceutical company GSK] for the treatment of [malignant pleural mesothelioma], advanced solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, bladder cancer, cervical cancer, esophageal, urothelial cancer, clear renal … More
Occupational exposure to cosmetic talc and mesothelioma in barbers, hairdressers, and cosmetologists: A systematic review of the epidemiology
Inhalation exposure to cosmetic talc has generated much scientific debate regarding its potential as a risk factor for mesothelioma, a rare, but fatal cancer. Barbers, hairdressers, and cosmetologists have regularly used cosmetic talc-containing products, but the collective epidemiological evidence … More